Collection of Biological Specimens from Volunteers or Patients with Multiple Myeloma and other Plasma Cell Dyscrasias Read more
Use of Bruton tyrosine kinase inhibitors (BTKI) in patients with Waldenstrom macroglobulinemia (WM) with neuropathy and Bing-Neel syndrome, and non-IgM lymphoplasmacytic lymphoma Read more
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma Read more
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination with Elranatamab in Participants with Relapsed and/or Refractory Multiple Myeloma Read more
A Phase 1, Open-Label Study that will test BMS-986393 in combination with 3 dual agent combinations of BMS-986393 (a chimeric antigen receptor CAR T-cell) with investigational treatments {Alnuctamab, Mezigdomide or Iberdomide} for safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics. Read more
CAR-T Cell Therapy Outcomes in Relapsed/Refractory Multiple Myeloma: A Retrospective Analysis Myeloma: A Retrospective Analysis Read more
An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy Read more
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial) Read more
